HROW: מזומנים למניה אחת harrowinc.com

Harrow, Inc. is developing the largest direct-sales network of ophthalmology brands in the US, acquired from pharmaceutical behemoths. The cash per share visualizes this growth, where the parameter value reaches 2.02. This results from the consolidation of innovative products for surgeons and exceptional pricing power over scarce drugs, which guarantees a steady flow of liquidity.
פילוחי מדדים מקיפים ואנליטיקה עבור Harrow Inc (HROW)

Harrow, Inc. (HROW) investments in a high-paid staff of ophthalmologists require strict liquidity control, which this metric reflects through the ratio of net cash to the number of shares. By analyzing the change in cash per share, an investor assesses the balance between capital accumulation and its efficient utilization, where excess funds reduce profitability while a deficit creates financial risks.